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Obscures Critical Findings on Impact of Medications for 
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Background. No International Classification of Diseases, 10th revision (ICD-10), diagnosis code exists for injection drug use–
associated infective endocarditis (IDU-IE). Instead, public health researchers regularly use combinations of nonspecific ICD-10 
codes to identify IDU-IE; however, the accuracy of these codes has not been evaluated.
Methods. We compared commonly used ICD-10 diagnosis codes for IDU-IE with a prospectively collected patient cohort diag-
nosed with IDU-IE at Barnes-Jewish Hospital to determine the accuracy of ICD-10 diagnosis codes used in IDU-IE research.
Results. ICD-10 diagnosis codes historically used to identify IDU-IE were inaccurate, missing 36.0% and misclassifying 56.4% of 
patients prospectively identified in this cohort. Use of these nonspecific ICD-10 diagnosis codes resulted in substantial biases against the 
benefit of medications for opioid use disorder (MOUD) with relation to both AMA discharge and all-cause mortality. Specifically, when 
data from all patients with ICD-10 code combinations suggestive of IDU-IE were used, MOUD was associated with an increased risk of 
AMA discharge (relative risk [RR], 1.12; 95% CI, 0.48–2.64). In contrast, when only patients confirmed by chart review as having IDU-IE 
were analyzed, MOUD was protective (RR, 0.49; 95% CI, 0.19–1.22). Use of MOUD was associated with a protective effect in time to all-
cause mortality in Kaplan-Meier analysis only when confirmed IDU-IE cases were analyzed (P = .007).
Conclusions. Studies using nonspecific ICD-10 diagnosis codes for IDU-IE should be interpreted with caution. In the setting of an 
ongoing overdose crisis and a syndemic of infectious complications, a specific ICD-10 diagnosis code for IDU-IE is urgently needed.
Keywords. endocarditis; ICD-10; medications for opioid use disorder; opioid use disorder; persons who inject drugs.
Injection drug use–associated infective endocarditis (IDU-IE) 
is a preventable infection with substantial morbidity and mor-
tality. There is significant interest in quantifying the epide-
miology, microbiology, economics, and clinical outcomes of 
IDU-IE to identify comprehensive evidence-based treatments 
and opportunities for practice improvement [1]. However, 
IDU-IE remains challenging to study given difficulties in 
assembling representative study cohorts and the propensity 
for persons who inject drugs (PWID) to seek care at mul-
tiple health care locations during the course of a single illness. 
Administrative data can provide a unified source of informa-
tion for epidemiological studies given systematic collection of 
data over time. Several recent studies have sought to leverage 
these unique strengths to better understand IDU-IE [2–4].
Administrative data are constrained by the data set used (ie, 
who/what are included), the reason for its creation (they are 
often not created for the research in question), and the accuracy 
of the coding [5]. Many studies using administrative data never 
validate assumptions when building their cohort. Specifically, 
many studies do not include validation analyses on the diag-
nostic or procedural codes used [6]. Biases are often introduced 
based on the surrogates chosen for the diagnosis in question. 
For example, there is no specific ICD-10 diagnosis code for 
IDU-IE. Prior work using administrative data to evaluate out-
comes for IDU-IE rely on combinations of ICD codes for both 
endocarditis and opioid use disorders [3, 4, 7–9]. However, 
these codes include nonspecific conditions. Commonly used 
ICD-10 codes in endocarditis studies include “rheumatic heart 
disease” and “other valvular disorders.” The most common 
opioid use disorder code is also frequently applied to patients 
receiving prescription opioids from their physician for chronic 
pain. We hypothesized that the combined use of nonspecific 
ICD-10 codes likely overestimates the national prevalence of 
IDU-IE and underestimates the emergence of co-occurring 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article/7/10/ofaa414/5903351 by W
ashington U
niversity in St. Louis user on 27 D
ecem
ber 2020
2 • ofid • Marks et al
infectious diseases such as hepatitis B virus infection, all-cause 
mortality, and the use and benefit of medications for opioid use 
disorder (MOUD), including buprenorphine and methadone.
The aim of this study was to evaluate the accuracy of the most 
commonly used ICD-10 code combinations for identifying 
IDU-IE in administrative data sets. This included a validation 
study of existing ICD-10 codes to identify IDU-IE and an eval-
uation of the impact of misclassification on OUD outcomes re-
ported in prior IDU-IE administrative data research.
METHODS
Data Source and Study Design
We compared a prospectively identified cohort of PWID with 
IDU-IE secondary to injection opioid use with a retrospec-
tive cohort identified using nonspecific ICD codes from prior 
published studies [4]. Both cohorts were comprised of patients 
treated at Barnes-Jewish Hospital, a 1400-bed academic med-
ical center located in St. Louis, Missouri, between July 1, 2017, 
and May 1, 2020. We considered the prospective cohort the 
“gold standard” for the validation study.
Case Selection and Definitions
Patients in the prospective cohort were identified by infec-
tious diseases physicians during routine patient care as part of 
a quality improvement initiative and later a CDC Developing 
Healthcare Safety Research contract [10]. The case form spe-
cifies the type of invasive infection and the type of substance 
used; only patients who had injection opioid use–associated en-
docarditis were included in this analysis. Cases were manually 
reviewed by an infectious diseases (ID) physician (L.R.M.) to 
verify that they met inclusion criteria (current injection drug 
use contributing to current episode of infective endocarditis). 
A second physician (L.J.) reviewed 50% of the charts at random 
to assess for data concordance. Only individuals with evidence 
of endocarditis on prospective chart review were considered 
IDU-IE cases.
Patients in the retrospective cohort were identified for 
screening from admissions during the same time frame as the 
prospective cohort, through use of the ICD-10 codes listed in 
Supplementary Table 1. For inclusion in the retrospective co-
hort, patients must have had both ICD-10 code F11.xx and at 
least 1 of the following ICD-10 codes related to endocarditis 
documented: I38, I33.0, I33.9, I35.8, B37.6, T82.6, I05.9, I01.1, 
I08.0, I08.3, I08.9, I37.8, I07.9, A38.2.
To assess the validity of ICD-10 diagnosis codes for identifying 
IDU-IE admissions, patient charts were individually reviewed 
by an infectious diseases (ID) physician (M.J.D., L.R.M., 
N.S.N.) to evaluate (1) if the hospital admission was related to 
infective endocarditis, (2) what clinical problem prompted the 
documentation of the code F11, and (3) if the patient’s infective 
endocarditis was presumed secondary to injection drug use. 
Using an iterative process, all reviewers (L.R.M., M.J.D., and 
N.S.N.) reviewed 10% of the charts at random to assess for data 
concordance. This process was repeated until concordance was 
>90%.
Patient Characteristics
Patient comorbidities were identified using elements from the 
Elixhauser comorbidity index [11]. Patient demographics, clin-
ical covariates, 90-day readmission rates, against medical advice 
(AMA) discharge, and outcomes data were collected. Receipt of 
MOUD, comprised of buprenorphine, methadone, or either oral 
or intramuscular naltrexone, was assessed by review of medica-
tion administration records. Hepatitis B virus antigen, hepatitis 
C virus antibody, and causative pathogen were assessed by re-
view of microbiology data from the electronic medical record 
(EMR). Mortality was assessed using both the EMR and the 
National Social Security Death Index. Patients were censored 
at either 1 year of postdischarge follow-up or May 1, 2020. We 
defined rural and urban location using patient zip codes for lo-
cation data and Federal Office of Management and Budget def-
initions, categorizing all micropolitan and noncore counties as 
“rural” and all metropolitan counties as “urban” [12, 13].
Statistical Analyses
Performance of the ICD-10 codes for identifying IDU-IE ad-
missions as determined by physician chart review was com-
pared with the prospectively collected cohort. Chi-square and 
Fisher exact tests were used to compare categorical variables. 
Pooled 2-sample t tests were used to compare continuous 
variables. Sensitivity for IDU-IE was calculated for ICD-10 
hospital discharge data, accepting physician review as a “refer-
ence standard.” Relative risk ratios (RRs) with 95% confidence 
intervals were calculated to determine the predictors of AMA 
discharge. Kaplan-Meier estimates were used to describe the 
survival distribution for time to readmission. The log-rank 
statistic was used to test the difference in time to readmis-
sion. Descriptive statistics were calculated using SPSS, version 
26 (Armonk, NY, USA). Figures were created using GraphPad 
Prism 9 (San Diego, CA, USA). This study was approved by the 
Washington University Institutional Review Board.
RESULTS
Utility of ICD-10 Codes for Identification of IDU-IE
Few studies have validated ICD code algorithms for IDU-IE. 
A  recent systematic review of the validity of ICD codes in 
identifying medical complications of illicit drug use found 
that no 2 studies have validated the same algorithm despite 
similar target conditions [14]. An ICD-10 code algorithm 
comprised of code F11.xx plus at least 1 endocarditis-related 
code (Supplementary Table 1) identified a total of 188 pa-
tients over the study period. However, ID physician review 
demonstrated that only 82 (43.6%) of these patients met 
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clinical criteria for IDU-IE. Furthermore, the ICD-10 algo-
rithm failed to identify an additional 44 patients identified 
on prospective review.
Prospective identification of IDU-IE over this time period 
yielded 114 patients. Of these, only 73 (64.0%) were also 
identified through electronic query using a combination of an 
endocarditis-related ICD-10 code (listed in Supplementary 
Table 1) and ICD-10 code F11. Patients identified by pro-
spective review but not ICD-10 codes were frequently noted 
to be missing an ICD code for their underlying substance 
use disorder, despite physician documentation that endocar-
ditis was related to underlying injection drug use. In some 
instances, the patient was noted to have multiple infections 
(eg, Staphylococcus aureus bacteremia complicated by en-
docarditis, septic arthritis, osteomyelitis, septic emboli, and 
endocarditis) with only some complications receiving an 
ICD-10 diagnosis code along with a diagnosis of septic shock. 
Chronic pain with prescription opioids was a commonly used 
ICD-10 diagnosis code that led to erroneous identification 
of IDU. Underling valvular disease was the most common 
ICD-10 diagnosis code that led to erroneous identification of 
IE. An additional 9 patients were identified by ICD-10 code 
combined with chart review, who were not identified by pro-
spective physician review. All patients identified by prospec-
tive physician review and the additional 9 patients identified 
by ICD-10 code combined with chart review were included 
as confirmed IDU-IE cases (total 123 cases) in our subse-
quent analysis. The sensitivity of ICD-10 code combinations 
for identification of IDU-IE cases was 65%.
Analyses of patient demographics between the confirmed 
IDU-IE cases and noncases showed a statistically significant dif-
ference in age, length of stay, and multiple chronic comorbidities 
(Table 1). Overall, patients with IDU-IE were younger (mean 
age, 34 years; compared with 54 years for noncases). The me-
dian length of stay for IDU-IE was 40 days vs 5 days for non-
IDU-IE cases. Patients with IDU-IE were more likely to lack 
stable housing (28% vs 7%; P = .001) and had higher rates of 
AMA discharge (15% vs 4%; P  =  .005). In addition to being 
older and more stably housed, non-IDU-IE cases had signifi-
cantly higher rates of diabetes, congestive heart failure, malig-
nancy, neurologic disorders, and depression.
Microbiologic characteristics significantly differed between 
the 2 groups, with IDU-IE cases more likely to be attributed 
to methicillin-susceptible Staphylococcus aureus, methicillin-
resistant Staphylococcus aureus, or streptococcal species 
(Table 1). While S. aureus remained the most common path-
ogen overall, non-IDU-IE cases were found to be attributed to a 
much broader group of pathogens including multiple different 
gram-negative pathogens. IDU-IE cases were additionally noted 
to have longer durations of bacteremia, with a mean of 4 days to 
blood culture clearance and multiple patients exceeding 7 days 
of bacteremia (longest duration, 16 days).
Effect of Inclusion of IDU-IE Cases Identified Using Nonspecific 
ICD-10 Code Combinations on Prospectively Identified Cases on Research 
Outcomes
We observed substantial differences in clinical outcomes for 
AMA discharge and all-cause mortality between the 2 cohorts 
(Table  2). Specifically, when the entire cohort of 229 patients 
(including all prospectively identified patients and patients 
with an ICD-10 code combination in Supplementary Table 1 
previously used to study patients with IDU-IE) was analyzed, 
receipt of MOUD was paradoxically associated with a trend 
toward an increased risk of AMA discharge (RR, 1.12; 95% 
CI, 0.48–2.64). In contrast, if only confirmed IDU-IE cases 
were analyzed, receipt of MOUD was associated with a trend 
toward a reduction in AMA discharges, as 6 of 62 (9.7%) pa-
tients left AMA in the MOUD group compared with 12 of 61 
(19.7%) patients who did not receive MOUD (RR, 0.49; 95% CI, 
0.19–1.22). Neither of these results was statistically significant; 
however, the apparent reversal in trend is striking. To investi-
gate the impact inclusion of noncases would have on mortality, 
we performed a Kaplan-Meier analysis of survival stratified by 
receipt of MOUD. Patients who received either methadone or 
buprenorphine during their hospitalization had lower mor-
tality rates than those who did not; however, the effect was not 
statistically significant when both IDU-IE cases and noncases 
were included in the overall population (P = .173). The effect of 
MOUD is magnified and becomes significant (P = .007) when 
only IDU-IE patients are analyzed (Figure 1).
DISCUSSION
Our results demonstrate that the ICD-10 diagnosis code com-
binations currently used to identify IDU-IE admissions in the 
administrative data research literature are not specific. Such 
ICD code combinations included non-IDU-IE cases with sub-
stantially different ages, comorbidities, lengths of stay, and 
microbiologic illnesses. Misclassification of IDU-IE cases in 
clinically relevant analyses biases analyses toward the null. 
IDU-IE-specific ICD-10 diagnosis codes are needed. Without 
such codes, analyses using administrative data to analyze the 
outcomes and epidemiology of IDU-IE should require physi-
cian review, have additional external validation, or be inter-
preted with caution.
Use of ICD code algorithms to identify cases of IDU-IE 
is becoming increasingly common as the opioid crisis con-
tinues. Large data sets, such as administrative data, have 
offered researchers the hope of identifying clinical practices 
that impact readmission rates and mortality, or identifying 
concerning pathogen trends early. However, our analysis 
raises concern that these data sets could contain non-IDU-IE 
cases, and actually consist of high volumes of patients with 
chronic pain or cancer-related pain, who have endocarditis 
not related to injection drug use. Inclusion of such patients 
could bias multiple important hypotheses toward the null. 
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Our study demonstrates that inclusion of non-IDU-IE cases 
(such as patients with chronic pain and endocarditis from 
other causes) obscures the benefit provided by MOUD on 
both AMA discharge and all-cause mortality. It is easy to im-
agine that the inclusion of non-IDU-IE cases would dramati-
cally alter the results of existing research, ranging from missed 
opportunities for provision of naloxone kits to the impact of 
interventions such as cardiac surgery and the cost of hospital-
izations for IDU-IE.
Microbiologic outcomes were also affected. Inclusion of non-
IDU-IE cases altered important epidemiologic information 
such as the rate of prolonged bacteremia, incidence of MSSA, 
and prevalence of viral hepatitis. These findings are consistent 
with work by other teams that has shown significant differences 
Table 2. Impact of Inclusion of Non-IDU-IE Cases on Outcomes of Potential Research Analyses
Clinical Research Question All Patients Analyzed Only Confirmed IDU-IE Cases Analyzed
Association between MOUD prescription at discharge and all-cause mortality at 1 y RR, 0.48; 95% CI, 0.17–1.36 RR, 0.26; 95% CI, 0.09–0.75
Association between MOUD prescription and AMA discharge RR, 1.12; 95% CI, 0.48–2.64 RR, 0.49; 95% CI, 0.19–1.22
Abbreviations: AMA, against medical advice; IDU-IE, injection drug use associated infective endocarditis; MOUD, medication for opioid use disorder includes buprenorphine, buprenorphine-
naloxone, methadone, and naltrexone; RR, relative risk. 
Table 1. Baseline Characteristics of Patients who Met Physician Criteria for IDU-IE vs Patients who Did Not Meet Physician Criteria for IDU-IE
Variable IDU-IE Case (n = 123), No. (%) Non-IDU-IE Case (n = 106), No. (%) P Value
Median age (q1, q3) 34 (25, 48) 54 (27, 78) <.001
Median LOS (q1, q3) 40 (1, 71) 5 (1, 23) <.001
Female 58 (47) 49 (46) .888
Black 43 (35) 41 (39) .464
Unhoused 28 (23) 7 (7) .001
Rural 26 (21) 16 (15) .236
Admission characteristics
Mean duration of bacteremia and/or fungemia (q1, q3) 4 (2, 7)  2 (1, 3) <.001
Received MOUD during hospitalization 62 (50) 5 (5) <.001
Hepatitis B Ag positive 6 (5) 1 (1) .006
Hepatitis C Ab positive 93 (76) 39 (37) <.001
Causative pathogen    
Methicillin-resistant S. aureus 34 (28) 15 (14) .011
Methicillin-sensitive S. aureus 54 (44) 11 (10) <.001
Streptococcal species 22 (18) 7 (7) .008
Candida 5 (4) 2 (2) .330
Outcomes
AMA discharge 18 (15) 4 (4) .005
Mortality 19 (15) 5 (5) .006
Comorbidities
Anemia 31 (25) 34 (32) .251
Congestive heart failure 15 (12) 25 (24) .023
Chronic pulmonary disease 21 (17) 27 (25) .120
Drug abuse 48 (39) 38 (36) .621
Depression 16 (13) 30 (28) .004
Diabetes 7 (6) 15 (14) .029
HIV and AIDS 2 (2) 2 (2) .881
Hypertension 20 (16) 43 (41) <.001
Liver disease 14 (11) 14 (13) .675
Obesity 5 (4) 9 (8) .163
Other neurological disorders 10 (8) 18 (17) .041
Psychoses 8 (7) 11 (10) .290
Renal failure 11 (9) 18 (17) .068
Malignancy 1 (1) 13 (12) <.001
Valvular disease 26 (21) 27 (25) .439
Weight loss 12 (10) 15 (14) .305
Bolded data indicate P values less than .05 (significant).
Abbreviations: AMA, against medical advice; IDU-IE, injection drug use associated infective endocarditis; MOUD, medication for opioid use disorder includes buprenorphine, buprenorphine-
naloxone, methadone, and naltrexone.
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in causative pathogens between IDU-IE vs non-IDU-IE cases 
[15]. This has important impacts on economic analyses and 
anticipated survival analyses for IDU-IE. Furthermore, public 
health analyses evaluating hepatitis screening and treatment 
for IDU-IE will likely be biased toward underscreening and 
undertreating IDU-IE patients.
Systematized Nomenclature of Medicine Clinical Terms 
(SNOMED CT) is a comprehensive and precise international 
clinical reference terminology frequently used in electronic 
health records for clinical documentation of problem lists. 
Clinicians should also be aware that several SNOMED CT 
codes may map to a single ICD-10 diagnosis code. For example, 
although “heroin addiction” and “opioid dependence with daily 
use” are clinically distinct conditions, both of these problem list 
items (also known as clinician display names) map to the same 
ICD-10 F11.xx diagnosis code (Table 3). This underlying issue 
illustrates the limited utility of ICD-10 billing and claims data in 
administrative data research targeting IDU-IE.
Prior work in other settings has demonstrated a similar lack 
of sensitivity when using ICD-10 diagnosis codes to identify 
IDU-IE [16]. To compensate, some researchers have suggested 
restricting age ranges [17, 18] or adding codes for blood-borne 
pathogens such as hepatitis C or HIV [18]. However, this selects 
for PWID who preferentially engage in needle-sharing and who 
may have different characteristics than those using syringe ex-
change facilities or taking other precautions. Similarly, some 
studies have attempted to remove any codes related to potential 
substance use disorders or evaluate the intersection of hepatitis 
C and infective endocarditis as a proxy for IDU-IE [7]. The re-
sults from our study underscore the limitations of this strategy; 
while confirmed IDU-IE cases in our cohort were more likely to 
have a positive hepatitis C antibody (76%), a sizeable percentage 
1.0A
B
No MOUD
MOUD
No MOUD-censored
MOUD-censored0.8
0.6
Su
rv
iv
al
0.4
0.2
0.0
0 90 180
Time, d
270 360
1.0
No MOUD
MOUD
No MOUD-censored
MOUD-censored0.8
0.6
Su
rv
iv
al
0.4
0.2
0.0
0 90 180
Time, d
270 360
Figure 1. A, Kaplan-Meier survival analysis of all patients with International Classification of Diseases, 10th revision, codes consistent with injection drug use–associated 
infective endocarditis (IDU-IE) stratified by receipt of medications for opioid use disorder (MOUD). B, Kaplan-Meier survival analysis of only patients confirmed on chart re-
view to have IDU-IE, stratified by receipt of MOUD.
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(32%) of non-IDU-IE cases had a positive hepatitis C antibody 
(P < .001).
Importantly, this study represents the first work to compare 
ICD-10 code algorithms to prospective identification of IDU-IE 
cases in a US health care setting. That ICD code algorithms not 
only incorrectly identify non-IDU-IE patients but also fail to 
identify patients who do have IDU-IE is of significant concern. 
Researchers using ICD code algorithms for this purpose should 
attempt to adjust for misclassification, if results are intended to 
inform clinical practice.
The limitations of this study include its single-center de-
sign and limited timespan (2017–2020). However, the lim-
itations related to nonspecific ICD codes would be present 
in all geographic regions. This study further focuses entirely 
on IDU-IE secondary to opioid use and does not evaluate 
IDU-IE secondary to injection of other substances, in-
cluding methamphetamines. As use of methamphetamines 
continues to increase nationwide, particularly in rural areas 
of the country, current and future analyses will likely under-
estimate the true prevalence of IDU-IE secondary to meth-
amphetamines and other nonopioids. Although our data 
suggest that MOUD reduce overall mortality, these analyses 
are complex, and our current models do not take into ac-
count patients switching between treatment groups during 
subsequent admissions. Thus, these results should be inter-
preted with caution.
The United States faces an ongoing syndemic of substance 
use disorders and life-threatening infectious complications as-
sociated with IDU, including infective endocarditis. It is critical 
that in the midst of this epidemic we have the ability to accu-
rately measure epidemiologic trends of this syndemic. While 
our work only evaluates 1 specific algorithm to identify IDU-IE 
secondary to opioids, the lack of sensitivity is troubling. Our 
findings demonstrate that the current state of combining mul-
tiple nonspecific ICD-10 codes fails to consistently identify 
this unique cohort and likely underestimates the benefit of ev-
idence-based treatments, such as MOUDs. We believe that the 
best way to overcome these significant problems is to issue a 
new ICD-10 code that is specific to injection drug use–associ-
ated infective endocarditis.
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